Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Financing Activities (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Cash from Financing Activities data on record, last reported at $219.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 22539.42% year-over-year to $219.4 million; the TTM value through Dec 2025 reached $222.5 million, up 366.81%, while the annual FY2025 figure was $222.5 million, 366.81% up from the prior year.
  • Cash from Financing Activities reached $219.4 million in Q4 2025 per TNGX's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $327.8 million in Q3 2021 and bottomed at -$746000.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $35.6 million, with a median of $843500.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: tumbled 3081.02% in 2021, then surged 70944.25% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$120000.0 in 2021, then soared by 539.17% to $527000.0 in 2022, then skyrocketed by 178.37% to $1.5 million in 2023, then crashed by 33.95% to $969000.0 in 2024, then soared by 22539.42% to $219.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $219.4 million in Q4 2025, $2.5 million in Q3 2025, and $581000.0 in Q2 2025.